Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2026-03-09 @ 7:22 AM
Study NCT ID:
NCT00538694
Status:
COMPLETED
Last Update Posted:
2019-11-14
First Post:
2007-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2000-10-31
Start Date Type:
ACTUAL
Primary Completion Date:
2001-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2001-09-30
Completion Date Type:
ACTUAL
First Submit Date:
2007-10-01
First Submit QC Date:
None
Study First Post Date:
2007-10-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-13
Last Update Post Date:
2019-11-14
Last Update Post Date Type:
ACTUAL